IQVIA Holdings Inc
IQV: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$727.00 | Zcnnrzq | Fqqqxhvh |
IQVIA Earnings: Strong Outsourced Clinical Trial Demand Drives Growth; Shares Undervalued
IQVIA reported third-quarter results highlighted by revenue of $3.7 billion, representing a nearly 5% increase versus the prior year. We maintain our fair value estimate of $250 per share, and we view the stock as undervalued, currently trading in 4-star territory about 26% below our fair value estimate.